Iterum Therapeutics ITRM shares are trading higher on Wednesday after the company announced, following its pre-NDA meeting, it plans to proceed with an NDA submission for sulopenem etzadroxil/ probenecid for the treatment of uncomplicated urinary tract infections.
Iterum is a pharmaceutical company. The company is engaged in developing and commercializing sulopenem to be the first and only oral and intravenous branded penem available globally. Its sulopenem program has the potential to offer a solution to the problem of antibiotic resistance and the toxicity limitations of existing agents.
Iterum Therapeutics shares traded up 123.46% to $1.44 on Wednesday during the time of publication. The stock has a 52-week high of $7.19 and a 52-week low of 51 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
